Largest Adcock Stakeholder To Decide Soon On $1.3 Billion CFR Offer
This article was originally published in PharmAsia News
A key stakeholder in Adcock Ingram Holdings said it could have a decision as early as next week on whether to join the 45% of shareholders in favor of selling a controlling interest to China's CFR Pharmaceuticals.
You may also be interested in...
Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.
US pharmacy group says that 10 to 12 states have indicated through an informal survey that they do not have the manpower or funding to implement the US FDA’s final MOU on inordinate compounding. They say what is at stake in these states is patient access to compounded medicines.
Mayo Clinic announces AI-based partnerships with Google and voice-analysis company Vocalis Health this week.